Sugi Predict

Sugi Predict / Compounds / SCHEMBL209802

SCHEMBL209802

SCHEMBL209802

CC(C)(C)OC(=O)N1CCN(c2ccc(C=O)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ LMNA P02545 2/20 0.64
▸ GPR119 Q8TDV5 7/20 0.56
▸ NAMPT P43490 1/20 0.55
▸ ABCB1 P08183 1/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ HTT P42858 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ TRIM24 O15164 1/20 0.50
▸ TRIM33 Q9UPN9 1/20 0.50
▸ PDK2 Q15119 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5573222 0.89 MAPT (0.76) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL17923084 0.89 MAPT (0.64) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL10153038 0.89 ALDH1A1 (0.54) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL13434251 0.88 GPR119 (0.75) MAPTALDH1A1LMNAGPR119
SCHEMBL4703663 0.85 MAPT (0.60) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL4703661 0.85 MAPT (0.60) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL22579225 0.85 MAPT (0.51) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL34474591 0.84 MAPT (0.53) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL29616802 0.84 ABCB1 (0.57) MAPTALDH1A1LMNAGPR119NAMPT
SCHEMBL3019659 0.84 ABCB1 (0.57) MAPTALDH1A1LMNAGPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119505231-A Copper-containing polymer, preparation thereof and application thereof in intracellular delivery of functional protein 华东师范大学 2025-02-25 — — CN claimed
CN-119118959-A Preparation method of 4- [4- (aminomethyl) phenyl ] piperazine-1-carboxylic acid tert-butyl ester 镇江市高等专科学校 2024-12-13 — — CN claimed
CN-117945989-A Lysosome-nucleolus migration type fluorescent probe, preparation method and application 山东大学深圳研究院 2024-04-30 — — CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 — — CN claimed
EP-4717317-A2 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2026-04-01 — — EP disclosed
EP-3641762-B1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2026-02-18 — — EP disclosed
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 — — US disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 — — US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 — — US disclosed
WO-2025245178-A1 PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS INNOVO THERAPEUTICS, INC. (US) 2025-11-27 — — WO disclosed
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation C4 THERAPEUTICS, INC. (US) 2025-10-14 — — US disclosed
US-6267913-B1 IN HOLOGRAPHYL, BIOLOGY, OPTICAL DATA STORAGE CALIFORNIA INSTITUTE OF TECHNOLOGY 2001-07-31 — — US disclosed
WO-1998021521-A9 TWO-PHOTON OR HIGHER-ORDER ABSORBING OPTICAL MATERIALS AND METHODS OF USE CALIFORNIA INST OF TECHN (US) 2000-03-02 — — WO disclosed
EP-0912175-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-09-08 — — EP disclosed
EP-0912175-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1999-05-06 — — EP disclosed
US-5854245-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-29 — — US disclosed
WO-1998021521-A1 TWO-PHOTON OR HIGHER-ORDER ABSORBING OPTICAL MATERIALS AND METHODS OF USE CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1998-05-22 — — WO disclosed
WO-1998000134-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation CRBN, CBL, STUB1 MAPT 3822/4885ALDH1A1 4548/4885LMNA 1209/4885
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBLC, CBL MAPT 4527/4885ALDH1A1 4035/4885LMNA 921/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 MAPT 3525/4885ALDH1A1 4701/4885LMNA 3465/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 MAPT 3707/4885ALDH1A1 4718/4885LMNA 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.